Managing Homozygous Familial Hypercholesterolemia with Lomitapide
Author Information
Author(s): Iannuzzo Gabriella, Calcaterra Ilenia Lorenza, Gentile Marco, Stanzione Claudia, de Ruberto Francesca, di Taranto Maria Donata, Cardiero Giovanna, Fortunato Giuliana, Minno Matteo Di
Primary Institution: University of Naples Federico II
Hypothesis
How can lomitapide be effectively managed in patients with homozygous familial hypercholesterolemia (HoFH)?
Conclusion
Lomitapide is effective in reducing LDL cholesterol levels in HoFH patients, but careful monitoring is necessary due to potential side effects.
Supporting Evidence
- Lomitapide was shown to induce a significant reduction in LDL cholesterol levels in a sample of HoFH patients.
- Patients experienced gastrointestinal symptoms as the most common side effects.
- Careful monitoring of liver enzymes is crucial during lomitapide treatment.
- Adding evinacumab helped maintain disease control while reducing lomitapide dosage.
Takeaway
This study looks at how a medicine called lomitapide helps kids and adults with a rare cholesterol problem called HoFH, but doctors need to watch for side effects.
Methodology
The study involved a literature review and a clinical experience report on six HoFH patients treated with lomitapide.
Limitations
The study is based on a small sample size and lacks comprehensive guidelines for monitoring and managing complications.
Participant Demographics
Three female and three male adult patients, with ages ranging from 31 to 62 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website